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Abstract 
An inductively coupled plasma mass spectrometry (ICP-MS)-based 
immunoassay has been developed to quantify aflatoxin M1 (AFM1) at ultra-
trace levels in milk samples. AFM1 detection is carried out by means of a 
competitive immunoassay using secondary biotinylated antibodies and 
streptavidin-conjugated Au nanoparticles. After acid addition, nanoparticles are 
decomposed and Au signal is registered by means of ICP-MS. Results 
demonstrate that, under optimum conditions, the limit of detection of the 
immunoassay (0.005 µg kg-1) is low enough to quantify AFM1 according to 
current international policies (including the more restrictive European one). 
Method accuracy and precision was checked by analyzing an AFM1 certified 
reference material and different milk samples spiked with known amounts of 
AFM1. AFM1 recovery values range from 80% to 102% whereas inter-assay 
and intra-assay precision are lower than 15%. Finally, this immunoassay 
methodology affords a higher dynamic working range (0.012-2.5 µg kg-1) than 
other immunoassay methodologies described in the literature. 
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1. Introduction  
Aflatoxins are secondary metabolites produced by different filamentous fungi 
(mainly Aspergillus species) and they are known to represent a high risk for 
human health due to their mutagenic and teratogenic effects. These substances 
could be found in different kinds of foods and animal feeds (e.g. cereals, cocoa, 
coffee, etc.) that have been in contact with fungi through the food chain under 
high temperature and humidity conditions (Bhat, Rai, & Karim, 2010).  
Aflatoxin M1 (AFM1) is the most significant aflatoxin in milk and dairy products. 
This compound is the hydroxylated form of the aflatoxin B1 (AFB1) and it is 
usually present in milk when animals have been fed with feedstuffs containing 
AFB1 (Flor-Flores, Lizarraga, López de Cerain, & González-Peñas, 2015). 
AFM1 has been classified as Group 2 human carcinogen by the International 
Agency of Research on Cancer (IARC, 2002). For this reason, and taking into 
account the significance of milk and milk products in human diet (especially for 
children), the maximum allowed levels of AFM1 are strictly regulated worldwide 
(Flor-Flores, Lizarraga, López de Cerain, & González-Peñas, 2015; Prandini, 
Tansini, Sigolo, Filippi, Laporta, & Piva, 2009). Food and Drug Administration 
from USA limits the concentration of AFM1 in milk and processed milk products 
at 0.50 µg kg-1 (FDA, 2005). However, European Community Legislation is even 
more restrictive and does not allow AFM1 levels in milk and infant formula 
above 0.050 and 0.025 µg kg-1, respectively (EC, 2002; EC, 2004). 
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AFM1 determination is usually carried out by means of high-performance liquid 
chromatography (HPLC) or immunoassays after an extraction treatment to 
reduce matrix effects and pre-concentrate the analyte (Shephard, 2008; Reiter, 
Zentek, & Razzazi, 2009). HPLC is considered the reference method for AFM1 
analysis (Dragacci, Grosso, & Gilbert, 2001; Diniz Andrade, Laine Gomez da 
Silva, & Dutra Caldas, 2013; Aguilera-Luiz, Plaza-Bolaños, Romero-González, 
Martínez Vidal, & Garrido Frenich, 2011; Beltran, Ibañez, Sancho, Cortés, 
Yusa, & Hernández, 2011). The detection of AFM1 is generally achieved by 
means of both fluorescence and mass spectrometry. However, HPLC analysis 
requires laborious sample preparation treatments to reduce matrix effects and 
improve analytical figures of merit. On the other hand, immunoassays (mainly 
Enzyme Linked Immunosorbent Assay, i.e., ELISA) are widely used for 
screening purposes due to their high sample throughput, simplicity and low 
budget (Picó, 2007; Guan, Li, Zhang, Zhang, & Jiang, 2011; Jiang, Wang, 
Nolke, Zhang, Niu, & Shen, 2013; Vdovenko, Lu, Yu, Sakharov, 2014).  
Inductively coupled plasma mass spectrometry (ICP-MS) is a powerful 
technique for inorganic analysis due to its: (i) low limits of detection (LoD) 
(usually in the µg kg-1-ng kg-1 range), (ii) good precision; (iii) multi-element 
capability, (iv) high dynamic range; and (v) the possibility to obtain analyte 
isotopic information (Bettmer, Montes-Bayón, Ruiz Encinar, Fernández, 
Fernández de la Campa, & Sanz-Medel, 2009). Traditionally, the analysis of 
organic molecules by ICP-MS has been limited to those analytes containing 
metals, metalloids and some non-metals (e.g. P or S) because of the difficulty to 
utilize C, H, N and O for quantification purposes at ultra-trace levels. However, it 
has been demonstrated that ICP-MS can be used as a detector for all kinds of 
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organic molecules (e.g. proteins, mRNA, DNA, etc.) after a derivatization 
procedure with a heteroatom or a compound containing a heteroatom (Tholey & 
Schaumlöffel, 2009; Kretschy, Koellensperger, & Hann, 2012). In this context, 
ICP-MS has been employed as a detector of proteins and biomolecules in 
immunoassays in view of it is quite straightforward to functionalized antibodies 
with elements detectable by this technique (Giesen, Waentig, Panne, & 
Jakubowski, 2012; Liu, Wu, Yang, Hou, & Lv, 2014). In general, antibodies (or 
any other species present in the immunoassay) are conjugated with elements 
presumably not present in biological samples, such as lanthanide based 
chelates or Au nanoparticles. The latter approach is especially advantageous to 
amplify the analytical response because of the significant number of quantities 
of Au atoms in each nanoparticle. The use of ICP-MS as a detector in 
immunoassays affords several attractive features such as: (i) specificity to 
heteroatom detection; (ii) compound-independent detection sensitivity; (iii) high 
elemental sensitivity and dynamic range; (iv) robustness (complex sample pre-
treatments are not required to diminish matrix effects); and (vii) multiplexing 
capabilities, since the antibodies can be conjugated with different heteroatoms 
and detected simultaneously. In spite of the above mentioned features, the use 
of ICP-MS-based immunoassays in food analysis has been limited so far. 
Nonetheless, these methods have been successfully applied to quantify peanut 
allergens (Careri, Elviri, Mangia, & Mucchino, 2007), ochratoxine A in wine 
(Giesen, Jakubowski, Panne, & Weller, 2010) and progesterone in milk 
(Montoro Bustos, Trapiella-Alfonso, Ruiz Encina, Costa-Ferández, Pereiro, & 
Sanz-Medel, 2012). 
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The goal of this work is to develop a new procedure to quantify AFM1 in milk 
samples by ICP-MS at the security levels required by the current international 
policies with accuracy and precision. The proposed methodology is based on a 
competitive immunoassay using secondary biotinylated antibodies and 
streptavidin-Au nanoparticles followed by Au detection by ICP-MS.  
 
2. Experimental 
2.1. Reagents and materials 
All solutions were prepared using ultrapure water (Milli-Q water purification 
system, Millipore Inc., Paris, France).  
Sodium carbonate, sodium hydrogen carbonate, monosodium phosphate, 
disodium phosphate, sodium chloride, biotinylated goat anti-rabbit IgG 
secondary antibody, AFM1 from Aspergillus flavus, AFM1-Bovine Serum 
Albumin conjugate (AFM1-BSA), streptavidin conjugated 40 nm Au 
nanoparticles from Streptomyces avidinii, polyethylene glycol sorbitan 
monolaurate (Tween 20) and HPLC-grade acetonitrile were purchased from 
Sigma-Aldrich (Steinheim, Germany). Bovine serum albumin (BSA) was 
obtained from Biowest (Nuaillé, France) whereas anti-AFM1 primary rabbit 
polyclonal antibody was obtained from Agrisera (Vännas, Sweeden). Iridium 
1000 mg L-1 stock solution was provided by Merck (Darmstadt, Germany). 
Thiourea, 69% w w-1 nitric acid and 35% w w-1 hydrochloric acid were 
purchased from Panreac (Barcelona, Spain).  
F16 maxisorp polystyrene microtiter plates were obtained from Thermo-
Scientific (Roskilde, Denmark). 
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2.2. Buffers and solutions 
Standard stock solution of AFM1 (10 µg L-1) was prepared in pure acetonitrile in 
an amber vial. AFM1-BSA was dissolved in 2 mL of phosphate buffer solution 
(PBS, 10 mol L-1 monosodium phosphate, 2 mmol L-1 disodium phosphate, 154 
mmol L-1 sodium chloride, pH 7.6) for a final concentration of 500 µg mL-1. Both 
solutions were kept at -20ºC. Primary rabbit polyclonal antibody was dissolved 
in 500 L ultrapure water and kept at 4ºC. 
The following solutions were employed in the ICP-MS-based immunoassay: (a) 
carbonate/bicarbonate buffer solution (15 mmol L-1 sodium carbonate and 35 
mmol L-1 sodium hydrogen carbonate, pH 9.6); (b) 1% w V-1 BSA in a PBS 
solution for plate blocking; (c) 1% w V-1 BSA and 0.05% V V-1 Tween 20 in PBS 
as the incubation media for the antibodies and streptavidin-Au (Strep-Au) 
media; (d) 0.05% V V-1 Tween 20 in PBS for washing microtiter plate wells and 
(d) 4% V V-1 nitric acid and 12% V V-1 hydrochloric acid for Au-nanoparticles 
digestion. 
 
2.3. Immunoassay procedure 
The analysis of AFM1 by ICP-MS is based on a competitive immunoassay 
(Giesen, Jakubowski, Panne, & Weller, 2010) in which varying amounts of free 
AFM1 inhibit the binding of specific antibodies to the solid phase coated with 
AFM1-BSA conjugate using secondary biotinylated antibodies and Strep-Au for 
ICP-MS detection (see Figure 1). First of all, the polystyrene microtiter plate 
wells were coated with 100 µL of the appropriate AFM1-BSA concentration in 
carbonate-bicarbonate buffer (step 1a). After a 1 hour incubation at room 
temperature, wells were washed 3 times and blocked with 1% w V-1 BSA in 
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PBS for 1 hour at room temperature. Simultaneously, samples or AFM1 
standards were mixed with the anti-AFM1 antibody solution (step 1b). The 
mixture was incubated 1 hour at room temperature and then 100 µL of it were 
transferred to the plate wells for another incubation step of 2.5 hours at room 
temperature (step 2). After washing -three times in order to eliminate the 
antigen-antibody complexes present in the solution as well as the free antibody, 
the microwell plates were sequentially incubated with 100 µL of a secondary 
biotinylated goat anti-rabbit IgG solution (step 3) and then with 100 µL of the 
Strep-Au solution (step 4). The incubation time for the previous steps was 1 
hour at room temperature followed by three washing steps. Finally, before ICP-
MS analysis, Au nanoparticles were digested (step 5) with 150 µL of the 
digestion acid mixture and spiked with 50 µL of a 1.0% w V-1 thiourea solution 
containing 2.5 µg L-1 Ir. All the AFM1 standards were analyzed in triplicate wells 
whereas samples containing unknown AFM1 amounts in quintuplicate wells. 
 
2.4. ICP-MS instrumentation 
According to the immunoassay procedure described above, AFM1 is quantified 
by means of ICP-MS using the 197Au+ signal. Despite the poor Au ionization in 
the plasma because of its high ionization potential (9.23 eV) (NIST atomic 
spectradatabase, 2016), the use of Au nanoparticles is especially advantageous 
to amplify the analytical response due to the high number of atoms present in 
each nanoparticle. ICP-MS measurements were performed by means of a 
7700x quadrupole-ICP-MS system (Agilent, Santa Clara, USA). Operating 
conditions were daily optimized to maximize 197Au+ following the instrument 
user’s guide (Table 1).  
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On account of the limited volume of sample available in the immunoassay (100 
µL), a micronebulizer (OneNeb, Ingeniatrics, Sevilla, Spain) coupled to a double 
pass quartz spray chamber (Agilent, Santa Clara, USA) was selected as the 
sample introduction system. Using this configuration, 197Au+ sensitivity for a 
sample uptake rate of 0.6 mL min-1 were 3-fold higher than those obtained using 
the standard nebulizer provided with the instrument (i.e., Micromist, Glass 
Expansion, Australia). These results were the expected taking into account the 
higher aerosol generation efficiency of the former nebulizer when operating at 
sample uptake rates in the order of L min-1 (Almagro, Gañán-Calvo, Hidalgo, & 
Canals, 2006). Initially, samples were tried to introduce into the spectrometer 
using self-aspirating conditions (i.e., without using a peristaltic-pump) as 
suggested by Giesen et al. (2010). However, signal reproducibility was poor 
(relative standard deviation, RSD, in the 5-8% range) and strong Au memory 
effects were registered. In fact, wash-out times (defined as the time required for 
reaching the 1% of the stable signal after blank introduction) of around 300 s for 
1 µg Au L-1 were obtained. This behavior could be attributed to the Au surface 
sticky nature (Giesen, Waentig, Panne, & Jakubowski, 2012) and the low 
sample uptake rate used (Mora, Maestre, Hernandis, & Todolí, 2003). To 
improve the reproducibility and the sample throughput, a flow injection analysis 
(FIA) procedure was employed. In this operating mode, samples were 
introduced into a carrier solution controlled by a peristaltic pump (Model 
Minipulse 3, Gilson, France) with the aid of a V-451 flow injection manifold 
(Upchurch Scientific, Silsden, United Kingdom) equipped with a 75 µL loop 
valve and a syringe. Carrier flow rate was set at 0.6 mL min-1 for high 
throughput analysis. To minimize Au wash-out times, different carrier solutions 
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(i.e. water, diluted nitric acid, etc.) were tested. Finally, a 1% V V-1 hydrochloric 
acid and 1% w V-1 thiourea mixture was chosen since it provides the lowest 
wash-out times (i.e., lower than 40 s) (Chen, Wee, & Brindle, 2000). 
Nonetheless, further improvement was feasible spiking the digestion acid 
mixture for Au nanoparticles with 1% w V-1 thiourea. Operating this way, no 
differences on wash-out times between Au and other elements (e.g. Mn, Ir, etc.) 
were observed (25 s). Finally, because of the discontinuous sample introduction 
mode of the FIA device, a peak-shape signal is obtained. Microsoft Excel 
software was employed to integrate 197Au+ signals manually.  
 
2.5. Calibration 
AFM1 determination was performed by means of a calibration curve built with 
the 197Au+ ICP-MS signal response of AFM1 standards of concentrations 
ranging from 0.001 to 5 µg kg-1. To improve accuracy and precision, Ir signal 
(193Ir+) was employed as internal standard for Au measurements. Ionization 
potential and m/z values for Ir are closed to the Au ones and, hence, matrix and 
drifts effects are expected to be similar for both elements (Vanhaecke, Vanhoe,  
Dams, & Vandecasteele, 1992). Therefore, the 197Au+ and 193Ir+ signal ratio was 
really employed to build the calibration curve and quantify AFM1. Iridium was 
added to the standards and the unknown samples with the acid mixture 
employed to digest Au nanoparticles after the immunoassay procedure (section 
2.3.) for a final concentration of 2.5 µg L-1. 
Finally, it is important to remark that, unlike the conventional ICP-MS analysis, 
the use of a competitive immunoassay makes that a high ICP-MS signal is 
related to a low AFM1 concentration. Thus, for instance, when no AFM1 is 
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present in the sample, all the primary antibody is retained in the microtiter plate 
and, as a consequence, the Au signal is maximum. Because of the sigmoidal 
curve response of the competitive immunoassay procedure, analyte 
determination was circumscribed to the curve section where there was a lineal 
relationship between the analyte signal and AFM1 concentration logarithm (i.e. 
0.012-2.5 µg kg-1 under optimum assay conditions). 
 
2.6. Samples 
The AFM1 certified reference material of whole milk powder, ERM-BD284 
(certified at 0.44±0.06 µg kg-1), was purchased from the Institute for Reference 
Materials and Measurements (European Commission Joint Research Centre, 
Geel, Belgium). In addition, five cow milk samples (i.e. raw, pasteurized and 
ultrahigh temperature pasteurized) were obtained from retail markets and 
supermarkets, stored at 4 ºC and analyzed before their respective expiration 
dates. 
 
2.7. Sample preparation 
The ERM-BD284 milk powder (10.0 g) was suspended in 50 mL of ultrapure 
water previously heated up to 50 °C using a stirring rod until a homogeneous 
mixture was obtained. After that, the solution was cooled and then diluted to 
100 mL using ultrapure water. So, AFM1 concentration in the reconstituted milk 
will be of 0.044 µg L-1. 
Both the certified and the commercial milk samples were pre-treated before the 
immunoassay using the procedure described by Huang et al. (2014) with some 
minor modifications. Thus, 200 µL of milk were mixed with 800 µL of acetonitrile 
  
11 
in an Eppendorf tube to extract AFM1 and remove matrix components. The 
extraction was performed using a vortex mixer for 2 min and sonicating the 
mixture for 30 min (Vibramix, J.P. Selecta S.A., Barcelona, Spain). Then, the 
extracts were centrifuged at 12100 g for 10 min at 4ºC (A 5804R Centrifuge, 
Eppendorf, Hamburg, Germany). After that, 800 µL of the supernatant were 
collected and evaporated up to dryness (miVac Quattro concentrator, Genevac 
Ltd, Suffolk, UK). The residue was reconstituted with 100 µL of PBS and then 
analyzed. 
 
3. Results 
3.1. Immunoassay optimization 
The competitive immunoassay described in the present paper has been 
developed with a polyclonal antibody produced in rabbits by immunization with 
BSA haptenized with AFM1. Considering that not only may this IgG preparation 
contain antibodies which react with BSA but also bovine milk contains a 
significant amount of this compound (1.2 % w V-1), an excess of BSA (1% w V-
1) was included in all the incubation media (see section 2.2) in order to 
neutralize any antibody activity specific to BSA in the assay. According to the 
supplier, the anti-AFM1 primary antibody is highly specific for AFM1 
determination with low cross-reactivity against other aflatoxins (AFB1 2%; 
aflatoxin B2 0.4%; aflatoxin G1 0.4% and aflatoxin G2 0.1%).  
Variables selected for the immunoassay optimization were the concentration of: 
(i) AFM1-BSA conjugate; (ii) anti-AFM1 primary antibody; and (iii) Strep-Au. The 
concentration of the secondary biotinylated antibody was not optimized and the 
dilution factor recommended by the manufacturer (1:2000) was employed. The 
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optimal conditions for the inhibition assay were chosen by checkerboard titration 
experiments as described for ELISA (Gee, Miyamoto, Goodrow, Buster, & 
Hammock,1988; Crowter, 2009). Briefly, decreasing amounts of M1 antigen 
(AFM1-BSA) were bound to microtiter wells and then incubated with serial 
dilutions of the primary antibody. ICP-MS readouts were evaluated to identify 
the optimal amount of AFM1-BSA per well as well as the corresponding dilution 
of primary antibody. Primary antibody was prepared by serial dilutions from 
1:500 to 1:8000 whereas AFM1-BSA concentration was modified between 0.07 
and 10 ng mL-1. For these experiments, Strep-Au dilution factor was kept 
constant at 1:500. In titration experiments, optimal conditions were defined as 
the amount of reagents (both, AFM1-BSA and primary antibody) producing 
signal-to-background ratio in ICP-MS close to the 80% of the maximal signal at 
plateau, characteristic of an antibody excess conditions (Crowter, 2009). The 
rationale for this criterion was that an assay dependent on inhibition of antibody 
binding, sensitivity would be maximal at the lowest concentration of antibody 
producing a consistent readout (i.e. minimal variability in replicates and an 
adequate dose-response relationship, when tested with the lowest possible 
amount of BSA-M1 bound to solid phase). Experimental results showed that 
optimum response was obtained for 0.35 ng L-1 of AFM1-BSA and a primary 
antibody dilution factor of 1:2000 (see Table S1, supplementary material). Once 
the optimum AFM1-BSA and primary antibody concentration were selected, 
Strep-Au dilution factor was optimized following a similar procedure to ensure 
the maximum 197Au+ response by the mass spectrometer. To this end, this 
parameter was modified between 1:1000 and 1:62.5. As expected, when the 
Strep-Au dilution factor was decreased, the Au response in ICP-MS improved. 
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A 6-fold signal improvement was registered when the dilution factor was varied 
from 1:1000 to 1:62.5 (see Figure S1, supplementary material). On the other 
hand, the precision in ICP-MS was also observed to be dependent on the Strep-
Au dilution employed. Gold signal RSD was improved up to 2-3% when Strep-
Au dilution decreased down 1:250. No further improvement of the RSD was 
obtained when lower dilution factors were used. Though lower Strep-Au 
dilutions provide higher Au signals in ICP-MS, no real improvement on 
analytical figures of merit was obtained (this topic will be discussed in detail 
below). For this reason, 1:250 Strep-Au dilution was selected for further studies 
as a compromise between analytical performance and costs. 
For calibration purposes, AFM1 standards were treated under the optimum 
competitive immunoassay experimental conditions (Figure 2). As it has been 
described in the experimental section, the sample containing the AFM1 and the 
primary antibody solution were incubated together (Figure 1, step 1.b) and then 
the mixture was transferred to the microtiter plate for a second incubation step 
(Fig1, step 2). Initially, the incubation time of each step was 1 hour. Analytical 
response in Figure 2 is expressed as the inhibition factor, defined as (S0-
S)·100/S0 where S0 is the maximal signal obtained in wells with no inhibition 
(i.e. no AFM1 was added) and S is the signal observed for each sample or 
standard preparation. Figure 2 shows that the concentration of AFM1 giving rise 
to a 50% inhibition factor (i.e., half maximal inhibitory concentration, IC50) for the 
ICP-MS-based immunoassay was 6.4 µg kg-1 whereas LoD (calculated as three 
times the standard deviation of the signal of 15 blank replicates (Jiang, Wang, 
Nolke, Zhang, Niu, & Shen, 2013) was around 0.070 µg kg-1, low enough to 
analyze AFM1 according to USA legislation (AFM1max level: 0.500 µg kg
-1). 
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However, unless a pre-concentration step would be implemented, the 
immunoassay could not be applied to the analysis of milk samples (AFM1max 
level: 0.050 µg kg
-1) and infant formula (AFM1max level: 0.025 µg kg
-1) under the 
more restrictive EU policy. In order to reduce the minimum AFM1 concentration 
level detectable and avoid costly and long sample pretreatments based on 
immunocolums for AFM1 preconcentration (Dragacci, Grosso, & Gilbert, 2001;  
Beltran, Ibañez, Sancho, Cortés, Yusa, & Hernández, 2011) the immunoassay 
optimization procedure was revised.  
Competitive immunoassay LoD is strongly linked to both primary antibody 
dilution factor and detector capability to recognize the primary antibody retained 
in the microtiter plate after the incubation step with the analyte containing 
sample. Thus, primary antibody dilution factor could be decreased to make the 
immunoassay more sensitive to low AFM1 levels. However, this means that 
primary antibody retained in the microtiter plate is less significant, thus making 
detection more difficult or even impossible. Accordingly, LoDs for the ICP-based 
immunoassay are expected to improve by increasing the efficiency of primary 
antibody retention in the microtiter plate and/or detection by ICP-MS. First of all, 
the incubation time of the AFM1 and the anti-AFM1 primary antibody in the 
microtiter plate coated with AFM1-BSA (step 2) was increased from 1 to 2.5 
hours with the aim to favor primary antibody retention on it. Operating in this 
way, it was feasible to reduce primary antibody dilution factor from 1:2000 to 
1:4000, thus improving sensitivity and LoDS without compromising robustness. 
As a consequence, the IC50 was approximately 10 times lower (0.42 µg kg
-1) 
and LoD decreased down to 0.005 µg kg-1 (Figure 2). The use of higher 
incubation times together lower primary antibody dilution factor (<1:4000) was 
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not further explored since sample throughput is negatively affected and LoD 
were low enough to quantify AFM1 according to the current international 
policies for this analyte. Alternatively, the feasibility of using lower Strep-Au 
dilution factor to improve ICP-MS detection was checked but no real 
improvement was obtained on LoDs. It should be taking into account that 
secondary antibody has a limited amount of biotin moieties and, as a 
consequence, signal amplification with Strep-Au is limited and could not 
compensate the lower amount of primary antibody retained in the microtiter 
plate. Probably, LoD could be improved using a sector field instrument or with a 
heteroatom-tag with a higher sensitivity in ICP-MS in order to use lower primary 
antibody dilution factors. 
 
3.2 Method validation  
The analytical methodology was evaluated according to European Conformity 
guidelines for analytical methods of food contaminants and mycotoxins (CE, 
2002; CE, 2006). First of all, method accuracy and precision was checked by 
analyzing an AFM1 certified reference material (ERM-BD284 milk powder, 
0.044±0.006 µg kg-1) and different milk samples spiked with known amounts of 
AFM1. Recovery test was performed spiking milk samples with AFM1 standard 
for a final concentration of 0.030 and 0.080 µg kg-1. All the samples were 
analyzed following the optimized immunoassay after an extraction treatment 
with acetonitrile to mitigate the effects of matrix components (e.g. proteins, fats 
etc.) on the antibody reaction. In fact, direct analysis of milk samples produced 
systematically AFM1 recovery values between 200-300%. Sample dilution to 
mitigate matrix effects was not explored due to its negative impact on LoDs. 
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Table 2 shows the recovery values for AFM1 in the certified reference material 
and in the spiked milk samples after the sample pre-treatment with acetonitrile. 
There is observed to be a good agreement between experimental and 
theoretical values. AFM1 recovery values ranged between 80% and 102%. 
These values were within the limits established by the EU for analyte 
concentrations below 1 µg kg-1 (-40%/+20%). The repeatability (intra-assay 
precision) of the method was determined by analyzing five replicates of each 
sample on the same day. The RSD of the AFM1 concentration levels was in the 
5%15% range. These values are the typical for immunoassays. The 
immunoassay reproducibility (inter-assay precision) of the proposed 
methodology was evaluated as the RSD of the measurements obtained for five 
independent immunoassays performed in five different days. The average 
AFM1 concentration obtained for the certified reference material was 
0.042±0.008 µg kg-1 which highlights the reproducibility of the assay. Similar 
conclusions were obtained for the spiked milk samples. Finally, the lower and 
the upper quantification limit of the immunoassay (LLOQ and ULOQ) were 
estimated (Guidance for Industry, Bioanalytical Method Validation, FDA, 2001). 
The LLOQ was defined as the analyte concentration that has a response at 
least 3 times that of a blank sample and repeatability lower than 20%. Similarly, 
the ULOQ was defined as the highest concentration standard that signal 
response has repeatability lower than 20%. LLOQ and ULOQ experimental 
values were 0.012 µg kg-1 and 2.5 µg kg-1, respectively. These results 
demonstrate the suitability of the ICP-MS-based immunoassay for AFM1 
determination in milk samples according to current security policies for this 
analyte. In fact, this methodology was applied to the analysis of different milk 
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samples (i.e. raw, pasteurized or ultra-high temperature pasteurized) but no 
AFM1 was detected (<0.005 µg kg-1).  
 
3.3 Comparison with other methodologies  
Analytical figures of merit of the ICP-MS-based immunoassay have been 
compared with those previously reported in the literature (Table 3). In general, 
the methodology developed in this work affords similar results to those obtained 
with chromatographic-based approaches or even other immunoassays. When 
comparing to chromatographic methods, poorer precisions are obtained (RSD 
nearly 2 to 3-fold higher), but no laborious sample pretreatments based on solid 
phase extraction or immunocolumns are required to preconcentrate and purify 
the AFM1. Sample pretreatment proposed in the present work is quite simple 
and it is only focused to eliminate the most significant matrix components 
without compromising sample throughput. Nevertheless, a 2-fold AFM1 
preconcentration factor is obtained operating on this way. On the other hand, 
due to immunoassay simplicity, reagents and solvent requirements (as well as 
wastes) are minimized. As regards other immunoassay procedures, ICP-MS-
based detection offers a wider linear range. Moreover, the proposed method not 
only shows lower background and blank levels but also an independent 
analytical response from incubation and storages times. In fact, standards and 
samples in the microtiter plate can be stored 2-3 weeks after acid mixture 
addition without significant effects on AFM1 results. However, sample 
throughput is partially degraded since microtiter plate wells are sequentially 
analyzed by the ICP-MS (3-4 hours to analyze a 96-well plate).  
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Up to date, the use of ICP-MS as a detector for mycotoxin analysis has been 
limited. In fact, it has only previously used to quantify ochratoxin A levels in wine 
by means of a competitive immunoassay methodology (Giesen, Jakubowski, 
Panne, & Weller, 2010). Though this previous work is not focused on AFM1, it is 
worth to compare both methodologies due to their similarities. Thus, Ochratoxin 
A detection was accomplished using secondary antibodies functionalized with 
Au nanoparticles and a sector field based ICP-MS. LoD using this configuration 
was stablished at 0.003 µg kg-1. A priori the high detection capabilities found 
could be attributed (at least in part) to the high sensitivities afforded by sector 
field mass spectrometers which makes feasible to use a low primary antibody 
dilution factor (1:10000). However, our work shows that AFM1 can also be 
quantified in the ng kg-1 range using a quadrupole-based mass spectrometer 
with a two-step signal amplification procedure based on a secondary 
biotinylated antibody and Strep-Au. The possibility of using quadrupole-based 
ICP-MS instruments to quantify toxin at ultra-trace levels is advantageous since 
they are the most spread mass spectrometers worldwide. Furthermore, 
precision for the AFM1 immunoassay was significantly better (5-15%) than that 
for the Ochratoxin A (5-40%). The origin of these differences is not clear due to 
the different procedures implemented in each immunoassay. Nonetheless, it 
points out that the precision achievable for the ICP-MS-based immunoassay is 
mainly limited by the immunological step since uncertainty derived by the ICP-
MS lays below 5%. 
 
 
4. Conclusions 
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This work demonstrates that ultra-trace analysis of AFM1 in milk is feasible 
using an ICP-MS-based immunoassay. Analytical figures of merit of this method 
fulfil the most restrictive current international policies for AFM1 analysis in milk 
and dairy products. Despite the fact that sample throughput could be 
deteriorated in relation to other immunoassay methodologies described in the 
literature, the use of ICP-MS for mycotoxin analysis has a great potential in food 
analysis due to a higher dynamic range, lower background levels and the 
independence of analytical response from incubation or storage times. In this 
regard, aflatoxin detection by means of ICP-MS could be still improved. Thus, 
LoDs for the competitive immunoassay employed in this work strongly depend 
on the primary antibody dilution factor and ICP-MS Au sensitivity to detect the 
amount of primary antibody retained in the microtiter plater. Therefore, detection 
capabilities could be probably improved (below ng L-1) using lower primary 
antibody dilution factor with a sector field mass spectrometer and/or tagging 
with higher sensitive hetereoatoms in ICP-MS. On the other hand, methodology 
sample throughput could be enhanced significantly determining other 
mycotoxins together AFM1 by means of antibodies functionalized with different 
heteroatoms. Operating on this way ICP-MS multiplexing capabilities are 
exploited and the use of a mass spectrometer could be more beneficial than 
other immunoassay detection procedures (e.g. ELISA, etc.). These experiments 
are currently being carried out in our laboratories. 
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Figure 1. Scheme of the competitive ICP-MS-based immunoassay for AFM1 
analysis in milk samples.  
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Figure 2. AFM1 calibration curve using different primary anti-AFM1 antibody 
concentrations. (--) primary antibody 1:2000/incubation time 1h; (--) primary 
antibody 1:4000/incubation time 2.5 h. AFM1-BSA concentration: 0.35 ng mL-1; 
secondary antibody dilution factor: 1:2000; Strep-Au dilution factor: 1:250.  
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Table 1. Operating conditions employed in ICP-MS 
Agilent 7700x ICP-MS 
Plasma forward power (W) 1550 
Argon flow rate (L min-1):  
        Plasma 15 
        Auxiliary 0.9 
        Nebulizer 1.01 
Sample introduction system  
Nebulizer OneNeb micronebulizer 
Spray chamber Double pass   
Carrier flow rate (mL min−1) 0.6 
Dwell time (µs) 0.5 
Number of sweeps 100 
Replicates 90 
Signal nature Area 
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Table 2. AFM1 recovery assay for different kind of milk samples. 
 AFM1 concentration (µg kg-1) Recovery (%)* 
Sample Certified/Spike Experimental 
Certified milk powder 0.0440.006 0.0380.006 8710 
Raw milk 
0.030 0.0270.003 9010 
0.080 0.0780.004 935 
Pasteurized milk 
0.030 0.0240.005 8017 
0.080 0.0780.002 982 
UHT whole milk 
0.030 0.0260.003 878 
0.080 0.0790.010 9910 
UHT whole milk (2) 
0.030 0.0280.003 937 
0.080 0.0820.008 10210 
Replicates: 5, * mean ± standard deviation 
 
  
  
Table 3. Comparison of diverse analytical methodologies proposed in the literature for the determination of AFM1 in milk samples 
Methodology 
Recovery  
(%) 
Precision  
(%) 
LOD  
(µg kg-1) 
Linear range  
(µg kg-1) 
Reference 
Indirect competitive immunoassay (ICP-MS) 80-102 5-15 0.005 0.010-2.5 This work 
Liquid-liquid extraction HPLC-Fluorescence 73-99 2-7 0.05 - Diniz Andrade, Laine Gomez da Silva, 
& Dutra Caldas, 2013  
IAC-HPLC-FD 116 5 0.010 0.01-0.20 Gurbay, Aydin, Girgin, Engin, & Sahin, 
2006 
MSFE-HPLC-FD 91-102 5 0.005 0.015-10 Hashemi, & Taherimaslak, 2014 
SPE-LC-MS 78-108 5-10 0.010 0.020-1 Sørensen, & Elæk, 2005 
UPHLC-MS/MS 
84-97 13 0.010 - 
Aguilera-Luiz, Plaza-Bolaños, 
Romero-González, Martínez Vidal, & 
Garrido Frenich, 2011 
80-110 <10 0.005 0.025-10 Beltran, Ibañez, Sancho, Cortés, 
Yusa, & Hernández, 2011 
Indirect competitive immunoassay (ELISA) 80-102 5-17 0.040 0.040-0.500 Pei, Zhang, Eremin, & Lee, 2009 
Direct competitive ELISA 90-110 <10 0.003 - Guan, Li, Zhang, Zhang, & Jiang, 
2011 
Direct competitive ELISA 93-98 5-8 0.008 0.004-0.250 Radoi, Targa, Prieto-Simon, & Marty, 
2008  
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Highlights 
 A novel ICP-MS-based immunoassay method to quantify AFM1 in milk samples 
is presented 
 AFM1 detection is based on a competitive immunoassay using gold 
nanoparticles 
 Limits of detection fulfill international policies for Aflatoxin M1  
 
